Jordi Rodón
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Hanna G, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodón J, Ahn M, Kim H, Schneeweiss A, Ribera J, DeAngelo D, Perez Garcia J, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl F, Garralda E. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Cancer Res Commun 2023; 3:1853-1861.
Sep 14, 2023A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Sep 14, 2023Cancer Res Commun 2023; 3:1853-1861
Hanna Glenn J, Stathis Anastasios, Lopez-Miranda Elena, Racca Fabricio, Quon Doris, Leyvraz Serge, Hess Dagmar, Keam Bhumsuk, Rodón Jordi, Ahn Myung-Ju, Kim Hye Ryun, Schneeweiss Andreas, Ribera Josep-Maria, DeAngelo Daniel, Perez Garcia Jose Manuel, Cortes Javier, Schönborn-Kellenberger Oliver, Weber Dirk, Pisa Pavel, Bauer Michael, Beni Laura, Bobadilla Maria, Lehal Raj, Vigolo Michele, Vogl Florian D, Garralda Elena
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Baird R, Fischer S, Azaro A, Harstrick A, Stumpp M, Leupin N, Dawson K, Fiedler U, Zitt C, Rodón J, Harris A, Lord S, Middleton M, Linossi C, Omlin A. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. J Clin Oncol 2020; 39:145-154.
Dec 10, 2020First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Dec 10, 2020J Clin Oncol 2020; 39:145-154
Baird Richard D, Fischer Stefanie, Azaro Analia, Harstrick Andreas, Stumpp Michael T, Leupin Nicolas, Dawson Keith M, Fiedler Ulrike, Zitt Christof, Rodón Jordi, Harris Adrian, Lord Simon, Middleton Mark, Linossi Constanza, Omlin Aurelius
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
van den Bent M, Zhang H, Balbin O, Vicente S, Cheng Y, Kirsilae T, Zhao S, Tiedt R, Rodón J, Tabatabai G, Jörger M, Lassman A, Wen P, Yung W, Sepulveda J, De Vos F, Azaro A, Wick W. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol 2019
Nov 27, 2019A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Nov 27, 2019J Neurooncol 2019
van den Bent Martin, Zhang Hefei, Balbin O Alejandro, Vicente Sergio, Cheng Yi, Kirsilae Tiina, Zhao Sylvia, Tiedt Ralph, Rodón Jordi, Tabatabai Ghazaleh, Jörger Markus, Lassman Andrew B, Wen Patrick Y, Yung W K Alfred, Sepulveda Juan, De Vos Filip, Azaro Analia, Wick Wolfgang
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Wicki A, Tzankov A, Hess V, Childs A, Hierro C, Rodón J, Hess D, Jörger M, von Moos R, Sessa C, Ritschard R, Prêtre V, Herrmann R, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 2018; 96:6-16.
Apr 13, 2018First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Apr 13, 2018Eur J Cancer 2018; 96:6-16
Wicki Andreas, Tzankov Alexandar, Hess Viviane, Childs Alexa, Hierro Cinta, Rodón Jordi, Hess Dagmar, Jörger Markus, von Moos Roger, Sessa Cristiana, Ritschard Reto, Prêtre Vincent, Herrmann Richard, Brown Nicholas, Xyrafas Alexandros, Bize Vincent, Hawle Hanne, Berardi Simona, Cmiljanović Nataša, Cmiljanović Vladimir, Stumm Michael, Dimitrijević Saša, Kristeleit Rebecca
Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?
Cassel J, Strasser F, Rodón J, Rid A, Poklepovic A, Jansen L, Hurst S, Higginson I, Arkenau T, Del Fabbro E, Miller F. Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?. J Pain Symptom Manage 2016
May 24, 2016Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?
May 24, 2016J Pain Symptom Manage 2016
Cassel J Brian, Strasser Florian, Rodón Jordi, Rid Annette, Poklepovic Andrew, Jansen Lynn A, Hurst Samia, Higginson Irene J, Arkenau Tobias, Del Fabbro Egidio, Miller Franklin G